





## Article

# Serum Fibroblast Growth Factor 21 Levels in Children and Adolescents with Hashimoto's Thyroiditis before and after L-Thyroxin Medication: A Prospective Study

Pavlos Drongitis <sup>1</sup>, Eleni P Kotanidou <sup>1</sup>, Anastasios Serbis <sup>1</sup>, Vasiliki Rengina Tsinopoulou <sup>1</sup>,  
Spyridon Gerou <sup>2</sup> and Assimina Galli-Tsinopoulou <sup>1,\*</sup>

<sup>1</sup> 2nd Department of Paediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece; droggpaul@yahoo.com (P.D.); epkotanidou@gmail.com (E.P.K.); tasos\_serbis@yahoo.com (A.S.); vasotsino@gmail.com (V.R.T.)

<sup>2</sup> Analyti Iatriki S.A., Biopathological Diagnostic Research Laboratories, 54623 Thessaloniki, Greece; spiros.gerou@gmail.com

\* Correspondence: agalli@auth.gr; Tel.: +30-2310994802

**Abstract:** *Backgrounds and Objectives:* Fibroblast growth factor 21 (FGF-21) is a complex hormone, sharing common sites of action with thyroid hormones. We investigated the association among FGF-21 levels, resting metabolic rate (RMR), and L-thyroxin (LT4) treatment in children and adolescents with Hashimoto's thyroiditis. *Materials and Methods:* A total of 60 youngsters with chronic autoimmune thyroiditis (AIT) (30 with subclinical hypothyroidism, 30 with euthyroidism) and 30 age and sex-matched healthy participants (5–18 years old) were enrolled in the study. Anthropometric, biochemical parameters, and RMR levels were assessed in all participants; serum FGF-21 levels were measured in the control group and the group with subclinical hypothyroidism before and six months after medication with LT4. *Results:* FGF-21 levels were lower in the treatment group compared with the healthy ones, but this difference was not statistically significant ( $p > 0.05$ ); despite the increase in FGF-21 levels after six months of LT4 treatment, this difference was not statistically significant ( $p > 0.05$ ). Free thyroxin (FT4) levels correlated well with FGF-21 levels ( $r = 0.399$ ,  $p < 0.01$ ), but further analysis revealed no interaction between these two variables. Both patient groups presented elevated triglyceride (TG) levels compared to controls ( $p < 0.05$ ). LT4 treatment had no impact on RMR and lipid or liver or glycaemic parameters. An increase in fat mass and fat-free mass were reported, independently of FGF-21 levels. *Conclusions:* In youngsters with subclinical hypothyroidism due to Hashimoto's thyroiditis, the serum FGF-21 levels are not significantly lower than in healthy individuals and increase after treatment with LT4 without a statistical significance. Further studies with a large number of young patients and severe hypothyroidism are recommended to confirm our results.

**Keywords:** Hashimoto's thyroiditis; fibroblast growth factor 21; resting metabolic rate; L-thyroxin; children; adolescents



**Citation:** Drongitis, P.; Kotanidou, E.P.; Serbis, A.; Tsinopoulou, V.R.; Gerou, S.; Galli-Tsinopoulou, A. Serum Fibroblast Growth Factor 21 Levels in Children and Adolescents with Hashimoto's Thyroiditis before and after L-Thyroxin Medication: A Prospective Study. *Medicina* **2021**, *57*, 1374. <https://doi.org/10.3390/medicina57121374>

Academic Editor: Manfredi Rizzo

Received: 31 October 2021

Accepted: 14 December 2021

Published: 17 December 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Hashimoto's thyroiditis, also referred to as chronic lymphocytic thyroiditis or chronic autoimmune thyroiditis (AIT), is a chronic autoimmune thyroid disorder characterized by increased titers of thyroid autoantibodies against thyroid peroxidase (Anti-TPOAb) and/or thyroglobulin (Anti-TgAb), lymphocytes infiltration, and thyroid tissue destruction [1,2]. AIT is a common form of thyroiditis in children and adolescents, reaching its incidence peak in early to mid-puberty and being 3–4 times more prevalent in females than males [1,3–5]. Hashimoto's thyroiditis in children and adolescents is often presented at the time of diagnosis in the form of normal/subclinical hypothyroidism [6]. Treating thyroid function disorders on the grounds of AIT in pediatric individuals is essential in order to secure normal neurocognitive and somatic growth [7].

It is well documented that thyroid hormones (THs) are involved in energy and lipid metabolism, thermogenesis, and body weight control, acting on several tissues. Thus, any change in thyroid status may affect body weight and metabolic rate [8,9]. On the other hand, fibroblast growth factor 21 (FGF-21) is a complex hormone involved in energy, lipid, and glucose metabolism, sharing common biochemical pathways and sites of action with THs. FGF-21 is synthesized and acts primarily on the liver, but weaker expression has also been described in muscle, pancreas, and adipose tissue. In addition, FGF-21 acts through endocrine and paracrine mechanisms, regulating metabolic pathways such as fatty acid oxidation, glucose uptake, and thermogenesis [9–12].

Recent animal and human studies have highlighted a close bidirectional relationship between FGF-21 and THs, partially elucidated [9,13–16]. Thyroid hormones regulate the expression of the FGF-21 gene in the liver and can also increase FGF-21 levels in vivo. However, it has also been suggested that some of their key actions are largely independent [17–19]. Data on FGF-21 levels and their metabolic role in pediatric patients with AIT are scarce. This study aimed to measure FGF-21 serum levels in children and adolescents with Hashimoto's thyroiditis and investigate any possible associations between FGF-21 serum levels and resting metabolic rate (RMR) and levothyroxine (LT4) treatment, or other clinical and biochemical parameters.

## 2. Materials and Methods

### 2.1. Participants

Between October 2015 and March 2020, a total of 172 children and adolescents, aged 5–18 years, were screened for AIT at the Pediatric Endocrinology Outpatient Clinic of Papanicolaou General Hospital and AHEPA University Hospital of Thessaloniki, Greece. Diagnosis of AIT was based on the presence of anti-thyroid autoantibodies (Anti-TPOAb and/or Anti-TgAb) and one or more of the following: clinical symptoms of thyroid dysfunction, goiter, or diffuse/irregular hypoechogenicity of the thyroid gland during ultrasound examination [6]. Among the 172 screened subjects, 36 with AIT (subclinical hypothyroidism) received levothyroxine (LT4) treatment [20]. A total of 6 of the 36 subjects were subsequently excluded from the study because they received medication for acute illness during their follow-up. The remaining 30 young patients comprised the "AIT treatment group". Among them, there were 23/30 youngsters (9 boys/14 girls) with a TSH < 10  $\mu$ IU/L, and 7/30 subjects (3 boys/4 girls) with TSH levels > 10  $\mu$ IU/L, all presented with FT4 values within a normal range and clinical features of hypothyroidism.

From the 172 initially screened subjects, 30/172 participants (12 boys/18 girls) with AIT and euthyroidism at the time of enrolment comprised the "AIT euthyroid group", whereas 30/172 age- and sex-matched healthy subjects (12 boys/18 girls) were also enrolled as "Control group" in the study.

All participants presented normal body mass index (BMI) for their age and sex, were drug-naïve for at least 3 months, followed no special diet, and did not present any chronic and/or acute disease or menstrual disorder. The AIT treatment group was followed for six months after starting LT4 treatment.

### 2.2. Clinical and Biochemical Data

Height was measured to the nearest millimeter with a wall-mounted stadiometer (Harpender Stadiometer, Holtain Limited, Crosswell Wales, UK). Waist, hip, and mid-upper arm circumference (MUAC) were measured with a Seca 201 measuring tape (Hamburg, Germany), and body weight was assessed with a Seca 711 scale (Hamburg, Germany). Body fat (BF) was assessed by the same experienced investigator using a skinfold caliper (Harpender Skinfold Caliper, Bate International, West Sussex, UK) and the equations proposed by Slaughter et al. [21]. Fat mass (FM), fat-free mass (FFM), FM index (FMI), and FFM index (FFMI) were calculated [22,23]. Body mass index (BMI) was calculated, and standard deviation scores (SDS) for BMI, height, and skinfolds were determined from the WHO growth charts using the LMS growth software. All subjects underwent a com-

plete physical examination, including posterior palpation of the thyroid gland, and were classified according to their puberty, applying Marshall and Tanner criteria [24,25].

Resting Metabolic Rate (RMR) was measured after a 12 h fast with a portable indirect calorimeter (FitMate™, Cosmed, Rome, Italy) [26], using a pediatric face mask following the protocols proposed by the study conducted by Fullmer et al. [27].

Blood samples were collected after overnight fasting, and serum levels of biochemical parameters were measured using standard methods and an ARCHITECTc 16000 clinical chemistry system (Abbott, Abbott Park, IL, USA). Concentrations of insulin, thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxin (FT4), as well as anti-thyroid peroxidase antibody (Anti-TPOAb), and thyroglobulin antibody (Anti-TgAb) titers were measured with an ADVIA Centaur XPT Immunoassay System (Siemens Healthcare GmbH, Erlangen, Germany). Laboratory's reference range for TSH, FT4, and FT3 levels was 0.80–3.99  $\mu$ IU/L, 10.55–20.72 pmol/L, and 4.21–7.57 pmol/L, respectively. The positive cut-off value of Anti-TPOAb and Anti-TgAb titers was >60 IU/mL. A thyroid gland ultrasound was performed by the same radiologist at the beginning of the study.

Serum FGF-21 levels were measured in patients with subclinical hypothyroidism and the control group. FGF-21 levels were determined in pg/mL using the Solid Phase Sandwich ELISA method according to the manufacturer's protocol (Quantikine® Elisa, Human FGF-21 immunoassay DF 2100, R&D Systems Europe Ltd., Abingdon Science Park, Abingdon, UK) with a sensitivity of 8.69 pg/mL, intra-assay CV < 4%, inter-assay CV < 5% and an assay range of 31.3–2000 pg/mL.

In order we have indirect information regarding the dietary state in participants, all participants, with the help of their parents and/or caregivers, completed the KIDMED questionnaire at their first visit. KIDMED questionnaire consists of 16 diet-related questions. A total score of 0–3 reflects a poor adherence to the Mediterranean diet, 4–7 an average compliance, and a score of 8–12 a suitable adherence [28,29].

### 2.3. Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics version 23.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were tested for normal distribution by the Kolmogorov–Smirnov or Shapiro–Wilk test. Data are presented as mean  $\pm$  standard deviation (SD) or medians with lower or upper quartiles. The differences between the examined groups of individuals were investigated using the Kruskal–Wallis test and ANOVA within the GLM function with Box-Cox transformation of the response variable to improve normality. The differences between the two groups of individuals were assessed using the Tukey post-hoc and Fisher least significant difference tests. When data were paired (e.g., before vs. after), we accounted for subject ID in our model. The correlations between two continuous variables were investigated using the Spearman rank correlation test. The level of statistical significance was set at  $p < 0.05$ .

## 3. Results

### 3.1. Baseline Characteristics of All Studied Groups

Baseline characteristics of all studied individuals are presented in detail in Table 1.

The total study population was grouped into three groups: the patient group with subclinical hypothyroidism (AIT treatment group,  $n = 30$ ), the patient group with AIT and euthyroidism (AIT euthyroid group,  $n = 30$ ), and the healthy group with no AIT and normal thyroid function (control group,  $n = 30$ ). Among all three groups, no significant differences in age, sex, Tanner stage, weight, height, standard deviation score for height (SDS Ht), BMI, %BF, FM, FFM, FMI, FFMI, waist circumference, hip circumference, and MUAC were identified ( $p > 0.05$ ). Patients with euthyroidism presented with a lower SDS BMI, but in the post-hoc analysis, that difference remained significant only between the patients with euthyroidism and subclinical hypothyroidism ( $p < 0.05$ ).


Table 1. Baseline characteristics of all participants.

Parameter	Control Group (n = 30)	AIT Treatment Group (n = 30)	AIT Euthyroid Group (n = 30)	p-Value
Age (yrs)	10.89 ± 2.29	10.99 ± 1.85	11.01 ± 1.93	0.970
SDS BMI	0.88 (−0.01–1.22)	0.73 (0.12–1.64)	0.36 (−1.07–1.16)	0.046
WAIST C. (cm)	69.33 ± 9.99	67.73 ± 9.32	65.65 ± 8.59	0.313
HIP C. (cm)	80.63 ± 10.58	81.38 ± 9.58	77.41 ± 9.69	0.267
MUAC (cm)	23.00 (20.00–25.25)	22.00 (20.00–25.25)	21.00 (19.75–23.62)	0.195
%BF	22.6 (18.53–31.8)	24.95 (21.15–32.07)	21.65 (16.47–29.83)	0.482
FMI (kg/ht <sup>2</sup> )	4.42 (3.17–5.98)	4.49 (3.43–7.06)	4.12 (2.64–5.63)	0.313
FFMI (kg/ht <sup>2</sup> )	14.66 (13.43–15.31)	14.27 (13.50–14.63)	13.47 (12.69–14.58)	0.103
TSH (μIU/L)	2.40 (1.95–3.06)	4.82 (3.99–9.66)	2.63 (2.13–3.09)	0.002
FT3 (pmol/L)	6.28 (5.71–6.79)	5.96 (5.44–6.40)	6.27 (5.91–6.71)	0.295
FT4 (pmol/L)	15.19 ± 1.93	14.29 ± 2.45	15.19 ± 2.57	0.313
Glucose (mmol/L)	4.88 (4.65–5.11)	4.86 (4.66–5.12)	4.74 (4.49–5.05)	0.302
Insulin (pmol/L)	48.12 (37.36–81.32)	64.58 (46.46–86.87)	54.65 (33.96–81.87)	0.472
HOMA-IR	1.50 (1.11–2.54)	1.93 (1.39–2.72)	1.62 (1.02–2.52)	0.143
TC (mmol/L)	3.88 ± 0.75	4.22 ± 0.84	4.22 ± 0.69	0.144
TG (mmol/L)	0.52 (0.45–0.65)	0.74 (0.52–0.89)	0.66 (0.56–1.02)	0.042
HDL (mmol/L)	1.38 (1.23–1.63)	1.43 (1.18–1.65)	1.54 (1.24–1.99)	0.157
LDL (mmol/L)	2.07 (1.65–2.56)	2.30 (2.01–2.92)	2.33 (2.04–2.64)	0.501
AST (IU/L)	24.50 (18.75–28.25)	23.00 (19.00–25.25)	27.50 (23.75–29.00)	0.253
ALT (IU/L)	14.50 (13.00–18.00)	15.00 (13.00–19.50)	16.50 (13.75–19.00)	0.410
γ-GT (IU/L)	12.00 (10.00–13.25)	12.00 (10.75–15.00)	12.00 (11.00–13.25)	0.284
ALP (IU/L)	217.00 (149.5–275.50)	200.00 (157.75–291.50)	217.00 (183.25–275.00)	0.475
RMR/Weight (kJ/kg per d)	150.46 (122.09–190.58)	131.08 (108.62–165.10)	168.74 (133.26–193.51)	0.089
FGF-21 (pg/mL)	217.36 (193.60–235.21)	182.71 (169.32–234.55)	Na	0.717

na = not available data. Data are expressed as mean ± SD or median (upper and lower quartiles). *p* = significant difference between groups at *p* < 0.05. Statistics: ANOVA within the GLM function and Box-Cox transformation of the response variable to improve normality. AIT = chronic autoimmune thyroiditis, SDS = standard deviation score, BMI = body mass index, C. = circumference, MUAC = mid-upper arm circumference, %BF = body fat percentage, FMI = fat mass index (FM/ht<sup>2</sup>), FFMI = fat-free mass index (FFM/ht<sup>2</sup>), TSH = thyroid-stimulating hormone, FT3 = free triiodothyronine, FT4 = free thyroxine, HOMA-IR = homeostatic model assessment for insulin resistance, TC = total cholesterol, TG = triglyceride, HDL = high-density lipoprotein, LDL = low-density lipoprotein, AST = aspartate aminotransferase, ALT = alanine aminotransferase, γ-GT = gamma glutamyltransferase, ALP = alkaline phosphatase, RMR = resting metabolic rate, FGF-21 = fibroblast growth factor-21.


Serum FGF-21 levels were found not significant lower in the AIT treatment group compared to the control group (182.71 pg/mL (169.32–234.55) vs. 217.36 (193.60–235.21) pg/mL), (*p* = 0.717). FGF-21 levels presented no difference between boys and girls (*p* > 0.05) in the total study population. After adjusting for sex, Tanner stage, TSH, FT3, FT4, triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), glucose, insulin, FM or FFM, the difference of FGF-21 serum levels between the AIT treatment and the control groups did not reach statistical significance (all *p* > 0.05).

A ROC curve analysis for FGF-21, TG, and TSH in the AIT treatment and control group was also performed in order to explore further if only FGF-21 and TG compared to TSH could serve as relative sensitive markers of peripheral hypothyroidism (Figure 1). The FGF-21 and TG ROC curves were far from the diagonal. The area under the curve (AUC) of FGF-21, AUC of TG, and AUC of TSH were different. Overall, the AUC of TSH was higher than the curves of TG or FGF-21 (0.898 vs. 0.661 vs. 0.602, respectively). The optimal cut-off point was 183.07 pg/mL for FGF-21 and 0.62 mmol/L for TG. The AUC of FGF-21 did not reach significance (*p* = 0.1853). Thus, TG and FGF-21 are found as much less sensitive markers than TSH (56.67 vs. 53.33 vs. 93.33, respectively) in the context of hypothyroidism.



**Figure 1.** ROC curves for FGF-21 (A), TG (B), and TSH (C) in the AIT treatment and control groups. FGF-21: fibroblast growth factor 21; TG: triglyceride; TSH: thyroid-stimulating hormone; AIT: chronic autoimmune thyroiditis.

Serum FGF-21 levels were significantly and positively correlated with FT4 levels in the total study population ( $r = 0.399$ ,  $p < 0.01$ ) (Figure 2); this positive association between the serum FGF-21 and FT4 levels was also strongly observed in the AIT treatment group ( $r = 0.385$ ,  $p < 0.05$ ).



**Figure 2.** Relationships between serum FGF-21 and FT4 levels in control and AIT treatment groups before and after treatment ( $n = 90$ ). Spearman correlation coefficients were as follows:  $r = 0.399$ ,  $p < 0.01$ . FGF-21: fibroblast growth factor 21; FT4: free thyroxine.


However, further analysis of variance showed no actual interaction between these two variables ( $p = 0.301$ ). In addition, serum FGF-21 levels did not correlate with any other anthropometric parameters or laboratory findings (lipidemic profile, glycemia, or liver function parameters) ( $p > 0.05$ ) (Table 2).

Triglyceride (TG) levels were significantly higher in patients with subclinical hypothyroidism and euthyroidism compared to healthy participants ( $p < 0.05$ ) in protocol baseline (Figure 3). However, among the two patient groups, the further pairwise comparison revealed that TG levels did not differ between the subclinical hypothyroid and the euthyroid individuals ( $p > 0.05$ ).

**Table 2.** Correlation of various parameters with FGF-21 in all participants.

Parameter	Correlation Coefficient ( <i>r</i> )	<i>p</i> -Value
%BF	0.015	0.887
FMI (kg/ht <sup>2</sup> )	−0.017	0.871
FFMI (kg/ht <sup>2</sup> )	−0.036	0.738
TSH (μIU/L)	−0.096	0.367
FT3 (pmol/L)	0.177	0.094
FT4 (pmol/L)	0.399	0.001 *
Glucose (mmol/L)	−0.035	0.741
Insulin (pmol/L)	0.078	0.463
HOMA-IR	0.083	0.436
TC (mmol/L)	−0.025	0.812
TG (mmol/L)	0.17	0.872
HDL (mmol/L)	0.089	0.405
LDL (mmol/L)	−0.23	0.833
AST (IU/L)	0.31	0.771
ALT (IU/L)	−0.035	0.742
γ-GT (IU/L)	−1.05	0.324
ALP (IU/L)	−0.060	0.576
RMR/FFM (kJ/kg per d)	0.088	0.411
RMR/Weight (kJ/kg per d)	0.064	0.551
KIDMED score	−0.200	0.126

\* Significant at the 0.01 level. *p* = significant correlation at *p* < 0.05. Statistics: Spearman rank correlation. BF = body fat, FM = fat mass, FMI = fat mass index (FM/ht<sup>2</sup>), FFM = fat-free mass, FFMI = fat-free mass index (FFM/ht<sup>2</sup>), TSH = thyroid-stimulating hormone, FT3 = free triiodothyronine, FT4 = free thyroxine, HOMA-IR = homeostatic model assessment for insulin resistance, TC = total cholesterol, TG = triglyceride, HDL = high-density lipoprotein, LDL = low-density lipoprotein, AST = aspartate aminotransferase, ALT = alanine aminotransferase, γ-GT = gamma glutamyltransferase, ALP = alkaline phosphatase, RMR = resting metabolic rate, KIDMED = Mediterranean diet index for kids, FGF-21 = fibroblast growth factor-21.



**Figure 3.** Serum TG levels of the control, AIT treatment, and AIT euthyroid groups. Values are expressed as median and range. TG: triglyceride; AIT: chronic autoimmune thyroiditis; NS: not significant.

Youngsters with subclinical hypothyroidism had lower RMR levels than those of the control and AIT euthyroid groups. Still, that difference was not significant after adjusting for FFM or body weight (all *p* > 0.05).

Although there were no differences between groups in the overall KIDMED score, more healthy subjects scored a suitable adherence to the Mediterranean diet than the patients (control group: 29.7% vs. AIT euthyroid group: 8.1% and AIT treatment group: 16.7%). In addition, healthy individuals consumed healthier eating compared to the patients. Indeed, control subjects reported rarer consumption of fast foods (16.7% vs. 35%), commercially baked foods (43.3% vs. 56.6%), sweet candies (56.7% vs. 75%), and on the other hand, more frequent consumption of nuts (46.7% vs. 28.3%), and a second daily serving of vegetables (33.3% vs. 18.3%) compared to patients.

### 3.2. Characteristics after LT4 Medication

LT4 therapy was initiated after baseline evaluation in participants with AIT and subclinical hypothyroidism. After 6 months of LT4 therapy, mean FGF-21 levels were not significantly increased from 182.71 pg/mL (169.32–234.55) to 198.43 pg/mL (183.86–248.42) (Table 3). Serum FGF-21 levels were not correlated with the FT4 levels after 6 months of therapy ( $r = 0.246$ ,  $p > 0.05$ ). After LT4 treatment, RMR levels did not increase significantly after adjusting for FFM or body weight ( $p > 0.05$ ).

**Table 3.** Characteristics of patients with Hashimoto's thyroiditis and subclinical hypothyroidism before and after 6 months of treatment.

Parameters	Before Treatment (n = 30)	After Treatment (n = 30)	p-Value
SDS BMI	0.73 (0.12–1.64)	0.88 (0.10–1.50)	0.915
WAIST C. (cm)	67.73 ± 9.32	69.2 ± 8.61	0.529
HIP C. (cm)	81.38 ± 9.58	81.50 ± 14.71	0.971
MUAC (cm)	22.00 (20.00–25.25)	23.00 (22.00–26.00)	0.215
%BF	24.95 (21.15–32.07)	24.06 (19.27–31.16)	0.955
FMI (kg/ht <sup>2</sup> )	4.49 (3.43–7.06)	8.98 (4.87–13.44)	0.001
FFMI (kg/ht <sup>2</sup> )	14.27 (13.50–14.63)	24.90 (18.52–31.31)	0.000
TSH (μIU/L)	4.82 (3.99–9.66)	4.03 (2.43–6.20)	0.054
FT3 (pmol/L)	5.96 (5.44–6.40)	5.90 (5.22–6.21)	0.055
FT4 (pmol/L)	14.29 ± 2.45	15.70 ± 2.45	0.037
Anti-TPOAb (IU/mL)	979.50 (135.27–2383.72)	800.00 (73.47–1687.20)	0.400
Anti-TgAb (IU/mL)	283.90 (69.40–500.00)	236.20 (87.95–500.00)	0.401
Glucose (mmol/L)	4.86 (4.66–5.12)	4.97 (4.72–5.19)	0.374
Insulin (pmol/L)	64.58 (46.46–86.87)	65.07 (47.85–87.43)	0.346
HOMA-IR	1.93 (1.39–2.72)	1.90 (1.57–2.65)	0.405
TC (mmol/L)	4.22 ± 0.84	4.19 ± 0.86	0.913
TG (mmol/L)	0.74 (0.52–0.89)	0.73 (0.56–0.93)	0.517
HDL (mmol/L)	1.43 (1.18–1.65)	1.46 (1.26–1.61)	0.865
LDL (mmol/L)	2.30 (2.01–2.92)	2.30 (1.93–2.82)	0.781
AST (IU/L)	23.00 (19.00–25.25)	22.00 (18.00–25.00)	0.096
ALT (IU/L)	15.00 (13.00–19.50)	15.50 (13.75–19.25)	0.315
γ-GT (IU/L)	12.00 (10.75–15.00)	11.00 (10.00–14.00)	0.652
ALP (IU/L)	200.00 (157.75–291.50)	224.50 (162.50–270.25)	0.414
RMR/Weight (kJ/kg per d)	131.08 (108.62–165.10)	142.51 (116.61–168.53)	0.517
FGF-21 (pg/mL)	182.71 (169.32–234.55)	198.43 (183.86–248.42)	0.734

Data are expressed as mean ± SD or median (upper and lower quartiles).  $p =$  significant difference between groups at  $p < 0.05$ . Statistics: ANOVA within the GLM function and Box-Cox transformation of the response variable and subject ID as a co-variate. SDS = standard deviation score, BMI = body mass index, C. = circumference, MUAC = mid-upper arm circumference, BF = body fat, FMI = fat mass index (FM/ht<sup>2</sup>), FFMI = fat-free mass index (FFM/ht<sup>2</sup>), TSH = thyroid-stimulating hormone, FT3 = free triiodothyronine, FT4 = free thyroxine, HOMA-IR = homeostatic assessment model for insulin resistance, TC = total cholesterol, TG = triglyceride, HDL = high-density lipoprotein, LDL = low-density lipoprotein, AST = aspartate aminotransferase, ALT = alanine aminotransferase, γ-GT = gamma glutamyltransferase, ALP = alkaline phosphatase, RMR = resting metabolic rate, FGF-21 = fibroblast growth factor-21.

Both FM and FFM were increased after LT4 treatment in patients with subclinical hypothyroidism (FM after treatment: 18.62 kg (10.83–29.01) vs. FM before treatment: 8.86 kg (7.35–16.69), FFM after treatment: 57.81 kg (43.19–64.22) vs. FFM before treatment:

30.57 kg (25.64–35.30),  $p = 0.001$  and  $p = 0.000$ , respectively). The increase in FM and FFM after LT4 therapy in the AIT treatment group was independent of the variation in serum FGF-21, BF, and BMI levels and remained significant after adjusting for age (FMI and FFMI  $p = 0.001$  and  $p = 0.000$ , respectively).

#### 4. Discussion

In this prospective study, serum FGF-21 levels were not significantly lower at baseline in children and adolescents with AIT and subclinical hypothyroidism, and they were not significantly increased after 6 months of LT4 therapy. FGF-21 showed low sensitivity as a possible marker of peripheral thyroid function and can not be used as such. FT4 concentrations correlated well with FGF-21 levels, but there were no actual interactions between these two variables. An increase in FM and FFM was reported after LT4 treatment in patients with subclinical hypothyroidism. Both AIT treatment and AIT euthyroid groups initially presented elevated TG levels compared to the control group.

Serum FGF21 levels variations are found in accordance with the previously reported levels in the current literature [12,30–32]. A large inter-individual variation in FGF-21 levels has been described [12]. Baseline serum FGF-21 levels were found not significantly lower in subjects with subclinical hypothyroidism than healthy ones, whereas 6 months of LT4 therapy did not significantly increase FGF-21 levels. The fact that this increment failed to reach statistical significance ( $p = 0.734$ ) could be attributed to the subclinical hypothyroidism that the study population exhibited and the prompt initiation of LT4 replacement therapy. A more clear trend was observed in the study of Wang et al. [15], where adults with overt hypothyroidism presented decreased plasma FGF-21 levels compared to controls and subjects with subclinical hypothyroidism. In this study, plasma FGF-21 levels of the group with hypothyroidism were measured significantly higher after LT4 treatment compared to baseline. However, in another study focused on adults, mean plasma FGF-21 concentrations were significantly higher in subjects with overt hypothyroidism than in subjects with either euthyroidism or subclinical hypothyroidism [14]. Discrepancies among different reports can be attributed to differences in study design, population age ranges, the severity of hypothyroidism, and technical aspects of different FGF-21 Elisa kits used for plasma or serum FGF-21 measurements.

Dyslipidemia in the context of hypothyroidism constitutes another source of FGF-21 levels discrepancy among different studies. It is well established that THs are involved in lipid metabolism, and thus, any thyroid function abnormality impairs that balance [1]. Overt hypothyroidism is often accompanied by increased TC, LDL, apolipoprotein B, lipoprotein A, and TG levels, but such alterations on lipidemic profile are usually not apparent in subclinical hypothyroidism [14]. Recent evidence shows that patients with hypothyroidism present lower TG and LDL levels than controls [33]. Furthermore, a study of 179 children and adolescents found a positive correlation between FGF-21 and TG levels in girls, concluding that elevated levels of FGF-21 and TG in girls compared with boys may be closely related [30]. Lastly, Catli et al. [34], studying healthy children and children with subclinical hypothyroidism, observed no significant differences in lipid parameters. In our study, higher serum TG levels were detected in the AIT patients (both with subclinical hypothyroidism and euthyroidism) compared with the healthy individuals ( $p < 0.05$ ). However, no significant difference in other lipid parameters was detected in the baseline. After 6 months of LT4 therapy, the lipidemic profile in our patients with subclinical hypothyroidism did not change significantly. Thus, the limited improvement in the lipidemic profile of our patients may partly explain why the serum FGF-21 levels were increased after 6 months of LT4 treatment, but this increment was not sufficient to prove statistical significance. A longer-term follow-up of our patients after LT4 initiation could provide further evidence.

In this study, serum FGF-21 levels were associated with FT4 levels, but further analysis showed no actual interaction between these variables, indicating possible unknown confounding factors. It has been proposed that FGF-21 and THs may act both synergistically



and independently [7,13,17,35]. In a previous animal study, the chronic infusion of FGF-21 significantly increased serum TSH, T3, and T4 levels [9]. In addition to these findings, Domouzoglou et al. [18] reported that T3 administration regulates FGF-21 transcription and increases circulating FGF-21 levels in animal models. On the other hand, a closer molecular look at the individual TH and FGF-21 pathways in those animal knock-out mice models revealed that distinct metabolic pathways are affected [18].

In a recent study in humans [15], a change in FGF-21 levels after LT4 treatment was well correlated with the increase in FT3 and FT4 values. Similarly, in our study, FGF-21 levels follow the same augmenting trend after LT4 treatment in children with subclinical hypothyroidism. However, it was not firmly established that there is a clear association between the rise in FGF-21 levels and the change in metabolic parameters in patients with hypothyroidism [12,15]. On the contrary, reports show a negative linear association between FT4 and plasma FGF-21 levels, even after multiple co-founders' adjustments (sex, BMI, TG, and glucose) [14]. Thus, it seems that there is a crosstalk between the metabolic pathways that involve THs and FGF-21 that needs further elucidation.

In terms of glycemic parameters and FGF-21, several studies have yielded equivocal results. In our study, glucose levels, fasting insulin, and HOMA-IR in the patients with subclinical hypothyroidism were within the normal range and did not differ among controls and AIT euthyroid individuals, at baseline or after LT4 treatment. Our results are in accordance with the study of Lee et al. [14]. No difference in glucose levels was detected, and the observed change in plasma FGF-21 levels was independent of glucose metabolism. Similarly, in another study in adults, fasting glucose variation did not differ between groups at baseline, although a significant difference in HOMA-IR was reported. However, FGF-21 was not significantly correlated with HOMA-IR [15]. Hanks et al. [35] showed that FGF-21 was inversely associated with HOMA-IR in boys 7–12 years of age but not in girls. In another study in a pediatric population, no relation between FGF-21 levels and glucose and insulin levels changes during an oral glucose tolerance test was described [30]. More recently, Lei et al. [33] reported no significant baseline differences in fasting glucose and 2 h postprandial glucose levels among the hypothyroidism, euthyroidism, and controls groups. However, insulin and HOMA-IR values were lower in the young patients with hypothyroidism. A study with 70 children with obesity and 45 without obesity showed that FGF-21 levels were significantly correlated with HOMA-IR after adjusting for BMI, TG, HDL, and adiponectin levels [32].

Although the role of THs in RMR is well described [8,36,37], we were unable to detect a difference in RMR values between the studied groups, even after LT4 treatment. Furthermore, our study reported no significant correlation between serum RMR and FGF-21 levels after FFM and body weight adjustment. This finding could be explained by the fact that all participants presented with subclinical hypothyroidism and were promptly treated with LT4.

A well-described association exists between FGF-21, THs, and diet [11,38]. Our subjects did not follow any specific diet plan as part of the inclusion criteria. The overall KIDMED score was not significantly different between the studied groups, and it was not correlated with serum FGF-21 levels. However, the effect of diet on FGF-21 levels cannot be excluded, as healthy subjects in our study reported specific healthier eating habits (e.g., less junk food, fewer sweets, and more vegetables and nuts).

Finally, in the AIT treatment group, a notable increase in the FM and FFM levels after LT4 treatment was observed ( $p < 0.05$ ), even after adjusting for age. That increment was independent of FGF-21 levels, the overall adiposity, and the BMI. These effects could be explained by restoring THs levels and their subsequent impact on orexigenic neuropeptides, leptin levels, and the hypothalamic-pituitary-thyroid (HPT) axis regulation [8]. In a previous study, no significant correlation between FGF-21 levels and DXA-derived fat percentage or BMI in healthy children has been detected [30], although more recently, an inverse association between FGF-21 levels and lean mass in girls was described, independently of FM [35]. On the other hand, in adults with hyperthyroidism, the serum FGF-21

levels have been negatively associated with %BF [16]. The different body composition assessment techniques that were used make the comparison of the above results challenging. At the same time, the biochemical pathways involved in this process should be further investigated.

The present study has some limitations that need to be recognized. The design of the study as a prospective cross-sectional protocol does not presuppose randomization; the sample size was relatively small. Serum FGF-21 levels were not measured in AIT euthyroid patients, as previous animal studies revealed that exogenous FGF-21 administration to hypothyroid animal models led to similar serum and liver lipid metabolites and gene expression changes in both hypothyroid and euthyroid mice [18]. Most of the participants did not have severe long-standing hypothyroidism before starting LT4 treatment, making it more difficult to detect the subtle, if any, metabolic changes that such pediatric patients develop.

## 5. Conclusions

To the best of our knowledge, this was the first attempt to study FGF-21 levels in relation to RMR and LT4 therapy in pediatric patients with Hashimoto's thyroiditis. The present study found that serum FGF-21 levels are not significantly different between the healthy subjects and those with AIT and subclinical hypothyroidism. More specifically, serum FGF-21 levels are lower in children and adolescents with AIT and subclinical hypothyroidism compared to healthy controls, without reaching statistical significance. The decrease in serum FGF-21 levels in children and adolescents with AIT and subclinical hypothyroidism is not so evident as in the case of overt hypothyroidism due to Hashimoto's thyroiditis. Serum FGF-21 levels tend to increase but not significantly, 6 months after LT4 treatment. Finally, LT4 therapy for 6 months has no apparent effect on RMR levels, lipid concentrations, or liver or glycemic parameters. Further studies with a larger number of young patients with severe hypothyroidism are needed to confirm the association between FGF-21 levels and thyroid function.

**Author Contributions:** Conceptualization, A.G.-T. and P.D.; methodology, A.G.-T., P.D. and S.G.; software, P.D.; validation, A.G.-T. and P.D.; formal analysis, P.D., E.P.K. and S.G.; investigation, A.G.-T. and P.D.; resources A.G.-T.; data curation, P.D.; writing-original draft preparation, P.D.; writing-review and editing, A.G.-T., E.P.K., A.S. and V.R.T.; visualization, P.D., E.P.K. and A.S.; supervision, A.G.-T.; project administration, A.G.-T.; funding acquisition, A.G.-T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by grants from the Research Committee of the Aristotle University of Thessaloniki. A.U.TH Research Committee, 3rd September Str.-University Campus, 54636 Thessaloniki, Greece, research@rc.auth.gr; project: "Pediatric and Adolescent Endocrinology" code project 89650 (CPV 85148000-8), Principal Investigator: Assimina Galli-Tsinopoulou. The contents of this publication are solely the authors' responsibility and do not necessarily represent the official views of RCAUTH.

**Institutional Review Board Statement:** The study protocol was conducted according to the criteria of the Declaration of Helsinki, was approved by the Bioethics and Ethics committee of the School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki (protocol number 204 on 23.3.2016), and was also registered in the [ClinicalTrials.gov](https://www.clinicaltrials.gov) database (NCT02725879).

**Informed Consent Statement:** All participants, their parents, and/or caregivers were informed, and a written consent form was obtained before inclusion in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical reasons.

**Acknowledgments:** We warmly thank the following for their valuable advice throughout the study: Dalia Malkova, School of Medicine, Dentistry and Nursing, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, UK and Eleni Papakonstantinou 1st Laboratory of Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

- Vukovic, R.; Zeljkovic, A.; Bufan, B.; Spasojevic-Kalimanovska, V.; Milenkovic, T.; Vekic, J. Hashimoto Thyroiditis and Dyslipidemia in Childhood: A Review. *Front. Endocrinol.* **2019**, *10*, 868. [[CrossRef](#)]
- Kaličanin, D.; Brčić, L.; Ljubetić, K.; Barić, A.; Gračan, S.; Brekalo, M.; Lovrić, V.T.; Kolčić, I.; Polašek, O.; Zemunik, T.; et al. Differences in food consumption between patients with Hashimoto's thyroiditis and healthy individuals. *Sci. Rep.* **2020**, *10*, 10670. [[CrossRef](#)]
- Özen, S.; Berk, Ö.; Şimşek, D.G.; Darcan, Ş. Clinical Course of Hashimoto's Thyroiditis and Effects of Levothyroxine Therapy on the Clinical Course of the Disease in Children and Adolescents. *J. Clin. Res. Pediatric Endocrinol.* **2011**, *3*, 192–197. [[CrossRef](#)]
- Skarpa, V.; Kousta, E.; Tertipi, A.; Anyfandakis, K.; Vakaki, M.; Dolianiti, M.; Fotinou, A.; Papathanasiou, A. Epidemiological characteristics of children with autoimmune thyroid disease. *Hormones* **2011**, *10*, 207–214. [[CrossRef](#)] [[PubMed](#)]
- De Luca, F.; Santucci, S.; Corica, D.; Pitrolo, E.; Romeo, M.; Aversa, T. Hashimoto's thyroiditis in childhood: Presentation modes and evolution over time. *Ital. J. Pediatrics* **2013**, *39*, 8. [[CrossRef](#)]
- Jonklaas, J.; Bianco, A.; Bauer, A.J.; Burman, K.D.; Cappola, A.R.; Celi, F.S.; Cooper, D.S.; Kim, B.W.; Peeters, R.P.; Rosenthal, M.S.; et al. Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid* **2014**, *24*, 1670–1751. [[CrossRef](#)]
- Mullur, R.; Liu, Y.Y.; Brent, G.A. Thyroid hormone regulation of metabolism. *Physiol. Rev.* **2014**, *94*, 355–382. [[CrossRef](#)] [[PubMed](#)]
- Yilmaz, U.; Tekin, S.; Demir, M.; Cigremis, Y.; Sandal, S. Effects of central FGF21 infusion on the hypothalamus–pituitary–thyroid axis and energy metabolism in rats. *J. Physiol. Sci.* **2018**, *68*, 781–788. [[CrossRef](#)]
- Fisher, F.M.; Maratos-Flier, E. Understanding the Physiology of FGF21. *Annu. Rev. Physiol.* **2016**, *78*, 223–241. [[CrossRef](#)] [[PubMed](#)]
- Xiao, F.; Zeng, J.; Huang, P.; Yan, B.; Zeng, X.; Liu, C.; Shi, X.; Wang, L.; Song, H.; Lin, M.; et al. Independent association of serum fibroblast growth factor 21 levels with impaired liver enzymes in hyperthyroid patients. *Front. Endocrinol.* **2019**, *9*, 800. [[CrossRef](#)]
- Keuper, M.; Häring, H.U.; Staiger, H. Circulating FGF21 Levels in Human Health and Metabolic Disease. *Exp. Clin. Endocrinol. Diabetes* **2020**, *128*, 752–770. [[CrossRef](#)]
- Adams, A.C.; Cheng, C.C.; Coskun, T.; Kharitonov, A. FGF21 Requires  $\beta$ klotho to Act In Vivo. *PLoS ONE* **2012**, *7*, e49977. [[CrossRef](#)]
- Lee, Y.; Park, Y.J.; Ahn, H.Y.; Lim, J.A.; Park, K.U.; Choi, S.H.; Park, D.J.; Oh, B.-C.; Jang, H.C.; Yi, K.H. Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile. *Endocr. J.* **2013**, *60*, 977–983. [[CrossRef](#)]
- Wang, G.; Liu, J.; Yang, N.; Hu, Y.; Zhang, H.; Miao, L.; Yao, Z.; Xu, Y. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism. *Eur. J. Intern. Med.* **2016**, *31*, 94–98. [[CrossRef](#)] [[PubMed](#)]
- Bande, A.; Kalra, P.; Dharmalingam, M.; Selvan, C.; Suryanarayana, K. Serum fibroblast growth factor 21 levels in patients with hyperthyroidism and its association with body fat percentage. *Indian J. Endocrinol. Metab.* **2019**, *23*, 557–562. [[CrossRef](#)] [[PubMed](#)]
- Bonde, Y.; Breuer, O.; Lütjohann, D.; Sjöberg, S.; Angelin, B.; Rudling, M. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. *J. Lipid Res.* **2014**, *55*, 2408–2415. [[CrossRef](#)]
- Domouzoglou, E.; Fisher, F.M.; Astapova, I.; Fox, E.C.; Kharitonov, A.; Flier, J.S.; Hollenberg, A.N.; Maratos-Flier, E. Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. *Endocrinology* **2014**, *155*, 2031–2040. [[CrossRef](#)] [[PubMed](#)]
- Zhang, A.; Sieglaff, U.H.; York, J.P.; Suh, J.H.; Ayers, S.D.; Winnier, G.E.; Kharitonov, A.; Pin, C.; Zhang, P.; Webb, P.; et al. Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver. *J. Endocrinol.* **2015**, *224*, 289–301. [[CrossRef](#)] [[PubMed](#)]
- Caturegli, P.; De Remigis, A.; Rose, N.R. Hashimoto thyroiditis: Clinical and diagnostic criteria. *Autoimmun. Rev.* **2014**, *13*, 391–397. [[CrossRef](#)] [[PubMed](#)]
- Vigone, M.C.; Capalbo, D.; Weber, G.; Salerno, M. Mild Hypothyroidism in Childhood: Who, When, and How Should Be Treated? *J. Endocr. Soc.* **2018**, *2*, 1024–1039. [[CrossRef](#)] [[PubMed](#)]
- Slaughter, M.H.; Lohman, T.G.; Boileau, R.A.; Horswill, C.A.; Stillman, R.J.; Van Loan, M.D.; Bembien, D.A. Skinfold equations for estimation of body fatness in children and youths. *Hum. Biol.* **1988**, *60*, 709–723.
- Al Shammari, E.; Bano, R.; Suneetha, E.; Alshammari, A.R.H. FFM Index, FM Index and PBF in Subjects with Normal, Overweight, and Obese BMI in Saudi Arabia Female Population. *J. Food Res.* **2015**, *5*, 40–48. [[CrossRef](#)]
- Wendel, D.; Weber, D.; Leonard, M.B.; Magge, S.N.; Kelly, A.; Stallings, V.A.; Pipan, M.; Stettler, N.; Zemel, B.S. Body composition estimation using skinfolds in children with and without health conditions affecting growth and body composition. *Ann. Hum. Biol.* **2017**, *44*, 108–120. [[CrossRef](#)]
- Marshall, W.A.; Tanner, J.M. Variations in pattern of pubertal changes in girls. *Obstet. Gynecol. Surv.* **1969**, *25*, 694–696. [[CrossRef](#)]
- Marshall, W.A.; Tanner, J.M. Variations in pattern of pubertal changes in boys. *Arch. Disease Child.* **1970**, *45*, 13–23. [[CrossRef](#)]

26. Nieman, D.C.; Austin, M.D.; Benezra, L.; Pearce, S.; McInnis, T.; Unick, J.; Gross, S.J. Validation of cosmed's FitMate™ in measuring oxygen consumption and estimating resting metabolic rate. *Res. Sport Med.* **2006**, *14*, 89–96. [[CrossRef](#)]
27. Fullmer, S.; Benson-Davies, S.; Earthman, C.P.; Frankenfield, D.C.; Gradwell, E.; Lee, P.S.; Piemonte, T.; Trabulsi, J. Evidence Analysis Library Review of Best Practices for Performing Indirect Calorimetry in Healthy and Non-Critically Ill Individuals. *J. Acad. Nutr. Diet* **2015**, *115*, 1417–1446.e2. [[CrossRef](#)] [[PubMed](#)]
28. Serra-Majem, L.; Ribas, L.; Ngo, J.; Ortega, R.M.; García, A.; Pérez-Rodrigo, C.; Aranceta, J. Food, youth and the Mediterranean diet in Spain. Development of KIDMED, Mediterranean Diet Quality Index in children and adolescents. *Public Health Nutr.* **2004**, *7*, 931–935. [[CrossRef](#)]
29. Štefan, L.; Prosoli, R.; Juranko, D.; Čule, M.; Milinović, I.; Novak, D.; Sporiš, G. The reliability of the mediterranean diet quality index (KIDMED) questionnaire. *Nutrients* **2017**, *9*, 419. [[CrossRef](#)] [[PubMed](#)]
30. Bisgaard, A.; Sørensen, K.; Johannsen, T.; Helge, J.; Andersson, A.-M.; Juul, A. Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents. *Int. J. Pediatric Endocrinol.* **2014**, *2014*, 7. [[CrossRef](#)]
31. Giannini, C.; Feldstein, A.E.; Santoro, N.; Kim, G.; Kursawe, R.; Pierpont, B.; Caprio, S. Circulating levels of FGF-21 in obese youth: Associations with liver fat content and markers of liver damage. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 2993–3000. [[CrossRef](#)] [[PubMed](#)]
32. Baek, J.; Nam, H.-K.; Rhie, Y.-J.; Lee, K.-H. Serum FGF21 Levels in Obese Korean Children and Adolescents. *J. Obes. Metab. Syndr.* **2017**, *26*, 204–209. [[CrossRef](#)] [[PubMed](#)]
33. Lei, Y.; Yang, J.; Li, H.; Zhong, H.; Wan, Q. Changes in glucose-lipid metabolism, insulin resistance, and inflammatory factors in patients with autoimmune thyroid disease. *J. Clin. Lab. Anal.* **2019**, *33*, e22929. [[CrossRef](#)]
34. Çatlı, G.; Anık, A.; Tuhan, H.; Böber, E.; Abacı, A. The Effect of L-Thyroxine Treatment on Hypothyroid Symptom Scores and Lipid Profile in Children with Subclinical Hypothyroidism. *J. Clin. Res. Pediatric Endocrinol.* **2014**, *6*, 238–244. [[CrossRef](#)]
35. Xiao, F.; Lin, M.; Huang, P.; Zeng, J.; Zeng, X.; Zhang, H.; Li, X.; Yang, S.; Li, Z.; Li, X. Elevated serum fibroblast growth factor 21 levels in patients with hyperthyroidism. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 3800–3805. [[CrossRef](#)] [[PubMed](#)]
36. Hanks, L.J.; Gutiérrez, O.M.; Bamman, M.M.; Ashraf, A.; McCormick, K.L.; Casazza, K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. *J. Clin. Transl. Endocrinol.* **2015**, *2*, 77–82. [[CrossRef](#)]
37. Mcaninch, E.A.; Bianco, A.C. Thyroid hormone signaling in energy homeostasis and energy metabolism. *Ann. N. Y. Acad. Sci.* **2014**, *1311*, 77–87. [[CrossRef](#)]
38. Hu, S.; Rayman, M.P. Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. *Thyroid* **2017**, *27*, 597–610. [[CrossRef](#)]